Sodium glucose cotransporter 2 inhibitors treatment in acromegalic patients with diabetes-a case series and literature review.
Acromegaly
Diabetes
Diabetic ketoacidosis
SGLT2i
Journal
Endocrine
ISSN: 1559-0100
Titre abrégé: Endocrine
Pays: United States
ID NLM: 9434444
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
received:
15
01
2021
accepted:
25
03
2021
pubmed:
17
4
2021
medline:
9
7
2021
entrez:
16
4
2021
Statut:
ppublish
Résumé
Diabetes mellitus (DM) represents one of the most frequent comorbidities in patients with acromegaly. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) represent an important class for diabetes management. However, limited data is reported regarding the use of this class in patients with acromegaly and diabetes. Reporting data regarding patients with acromegaly and diabetes under treatment with SGLT2i. 29 acromegalic patients with diabetes were identified. Treatment with SGLT-2i was documented in nine patients, out of them 5 females and 4 males with a mean age (SD) of 61 ± 12 yr. The mean (SD) duration of treatment with SGLT2i was 27.5 ± 7.3 months. Mean HbA1c before and after SGLT-2i initiation was 8.1 ± 1.1 and 7.0 ± 0.9% respectively. Mean IGF-1 level (SD) before SGLT-2i initiation was 177 ± 68 ng/mL and the mean GH level (SD) was 0.7 ± 0.5 µg/L. All nine patients are still under treatment with SGLT2i and none of them had reported any adverse reaction related to SGLT2i. The present article provides us for the first time with new data regarding the use of SGLT2i among acromegalic patients with diabetes.
Identifiants
pubmed: 33860432
doi: 10.1007/s12020-021-02718-w
pii: 10.1007/s12020-021-02718-w
doi:
Substances chimiques
Sodium-Glucose Transporter 2 Inhibitors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
65-70Références
L. Katznelson, E.R. Laws, S. Melmed et al. Acromegaly: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 99, 3933–3951 (2014)
doi: 10.1210/jc.2014-2700
M.R. Gadelha, L. Kasuki, D.S.T. Lim, M. Fleseriu, Systemic complications of acromegaly and the impact of the current treatment landscape: an update. Endocr. Rev. 40, 268–332 (2019)
doi: 10.1210/er.2018-00115
B. Zinman, C. Wanner, J.M. Lachin,EMPA-REG OUTCOME Investigators et al., Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117–2128 (2015)
doi: 10.1056/NEJMoa1504720
J.J.V. McMurray, D.L. DeMets, S.E. Inzucchi, L. Køber, M.N. Kosiborod, A.M. Langkilde, F.A. Martinez, O. Bengtsson, P. Ponikowski, M.S. Sabatine, M. Sjöstrand, S.D. Solomon,DAPA-HF Committees and Investigators, A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF). Eur. J. Heart Fail. 21, 665–675 (2019)
doi: 10.1002/ejhf.1432
C. Wanner, H.J.L. Heerspink, B. Zinman, S.E. Inzucchi, A. Koitka-Weber, M. Mattheus, S. Hantel, H.J. Woerle, U.C. Broedl, M. von Eynatten, P.H. Groop,EMPA-REG OUTCOME Investigators, Empagliflozin and kidney function decline in patients with type 2 diabetes: a slope analysis from the EMPA-REG OUTCOME trial. J. Am. Soc. Nephrol. 29, 2755–2769 (2018)
doi: 10.1681/ASN.2018010103
S. Frara, F. Maffezzoni, G. Mazziotti, A. Giustina, Current and emerging aspects of diabetes mellitus in acromegaly. Trends Endocrinol. Metab. 27, 470–483 (2016)
doi: 10.1016/j.tem.2016.04.014
M. Quarella, D. Walser, M. Brändle, J.Y. Fournier, S. Bilz, Rapid onset of diabetic ketoacidosis after SGLT2 inhibition in a patient with unrecognized acromegaly. J. Clin. Endocrinol. Metab. 102, 1451–1453 (2017)
doi: 10.1210/jc.2017-00082
E.A. Nyenwe, A.E. Kitabchi, The evolution of diabetic ketoacidosis: an update of its etiology, pathogenesis and management. Metabolism 65, 507–521 (2016)
doi: 10.1016/j.metabol.2015.12.007
J. Rosenstock, E. Ferrannini, Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care 38, 1638–1642 (2015)
doi: 10.2337/dc15-1380
N. Fleming, P.S. Hamblin, D. Story, E.I. Ekinci, Evolving evidence of diabetic ketoacidosis in patients taking sodium-glucose cotransporter 2 inhibitors. J. Clin. Endocrinol. Metab. 1, 105 dgaa200 (2020). https://doi.org/10.1210/clinem/dgaa200
doi: 10.1210/clinem/dgaa200
E. Ferrannini, E. Muscelli, S. Frascerra et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J. Clin. Invest 124, 499–508 (2014)
doi: 10.1172/JCI72227
C. Saponaro, F. Pattou, C. Bonner, SGLT2 inhibition and glucagon secretion in humans. Diabetes Metab. 44, 383–385 (2018)
doi: 10.1016/j.diabet.2018.06.005
G. Mazziotti, I. Floriani, S. Bonadonna, V. Torri, P. Chanson, A. Giustina, Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. J. Clin. Endocrinol. Metab. 94, 1500–1508 (2009)
doi: 10.1210/jc.2008-2332
A. Colao, M.D. Bronstein, P. Freda, F. Gu, C.C. Shen, M. Gadelha, M. Fleseriu, A.J. van der Lely, A.J. Farrall, K. Hermosillo Reséndiz, M. Ruffin, Y. Chen, M. Sheppard, P.C.S. Group, Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J. Clin. Endocrinol. Metab. 99, 791–799 (2014)
doi: 10.1210/jc.2013-2480
W.M. Drake, S.V. Rowles, M.E. Roberts, F.K. Fode, G.M. Besser, J.P. Monson, P.J. Trainer, Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to pegvisomant. Eur. J. Endocrinol. 149, 521–527 (2003)
doi: 10.1530/eje.0.1490521
Fleseriu, M., Biller, B.M.K., Freda, P.U., Gadelha, M.R., Giustina, A., Katznelson, L., Molitch, M.E., Samson, S.L., Strasburger, C.J., van der Lely, A.J., Melmed, S. A Pituitary Society update to acromegaly management guidelines. (2020) https://doi.org/10.1007/s11102-020-01091-7
P. Ocampo, J.M. Duarte, R. Barcia, C. Arévalo, Association between diabetic ketoacidosis and acromegaly. Medicine 78, 131–133 (2018)
A. Herrero-Ruiz, H.S. Villanueva-Alvarado, J.J. Corrales-Hernández, C. Higueruela-Mínguez, J. Feito-Pérez et al. Coexistence of GH-producing pituitary macroadenoma and meningioma in a patient with multiple endocrine neoplasia type 1 with hyperglycemia and ketosis as first clinical sign. Case Rep. Endocrinol. 2017, 2390797 (2017). https://doi.org/10.1155/2017/2390797
doi: 10.1155/2017/2390797
pubmed: 29225978
pmcid: 5687133
J. Weiss, A.J. Wood, J.D. Zajac, M. Grossmann, S. Andrikopoulos, E.I. Ekinci, Diabetic ketoacidosis in acromegaly; a rare complication precipitated by corticosteroid use. Diabetes Res. Clin. Pract. 134, 29–37 (2017)
doi: 10.1016/j.diabres.2017.08.023
H. Inaba, T. Funahashi, H. Ariyasu et al. Diabetic ketoacidosis in a patient with acromegaly and central diabetes insipidus treated with octreotide long-acting release. Diabetol. Int 10, 237–242 (2017)
doi: 10.1007/s13340-016-0301-z
N. Yoshida, H. Goto, H. Suzuki, K. Nagasawa, A. Takeshita et al. Ketoacidosis as the initial clinical condition in nine patients with acromegaly: a review of 860 cases at a single institute. Eur. J. Endocrinol. 169, 127–132 (2013)
doi: 10.1530/EJE-13-0060
R.V. Dosi, R.D. Patell, P.J. Shah et al. Diabetic ketoacidosis: an unusual presentation of acromegaly. BMJ Case Rep. 11, bcr2013010198 (2013)
H.J. Jiang, W.W. Hung, P.J. Hsiao, A case of acromegaly complicated with diabetic ketoacidosis, pituitary apoplexy, and lymphoma. Kaohsiung J. Med Sci. 29, 687–690 (2013)
doi: 10.1016/j.kjms.2013.08.002
P. Palakawong, R. Arakaki, Diabetic ketoacidosis in acromegaly: a case report. Endocr. Pract. 27, 1–15 (2012)
doi: 10.4158/EP12189.CR
P. Mewawalla, G. Jaiswal, M. Moustakakis et al. Refractory DKA as first presentation of acromegaly and a potential role for continuous venovenous hemofiltration in its successful management. Conn. Med. 75, 405–407 (2011)
pubmed: 21905534
M. Waterhouse, I. Sabin, N. Plowman, S. Akker, T.A. Chowdhury, A “growing cause” of diabetic ketoacidosis. BMJ Case Rep. 11, 2008.1226 (2009)
Y.L. Chen, C.P. Wei, C.C. Lee et al. Diabetic ketoacidosis in a patient with acromegaly. J. Formos. Med. Assoc. 106, 788–791 (2007)
doi: 10.1016/S0929-6646(08)60042-X
M. Lakhotia, R. Mathur, H. Singh et al. Diabetic ketosis as a presenting feature of acromegaly. J. Assoc. Physicians India 55, 377–378 (2007)
pubmed: 17844701
C. Erem, H.O. Ersöz, K. Ukinç et al. Acromegaly presenting with diabetic ketoacidosis, associated with retinitis pigmentosa and octreotide-induced bradycardia: a case report and a review of the literature. Endocrine 30, 145–149 (2006)
doi: 10.1385/ENDO:30:1:145
B. Kopff, S. Mucha, B.H. Wolffenbuttel et al. Diabetic ketoacidosis in a patient with acromegaly. Med. Sci. Monit. 7, 142–147 (2001)
pubmed: 11208511
S.A. Westphal, Concurrent diagnosis of acromegaly and diabetic ketoacidosis. Endocr. Pract. 6, 450–452 (2000)
pubmed: 11155217
C.C. Szeto, K.Y. Li, G.T. Ko et al. Acromegaly in a woman presenting with diabetic ketoacidosis and insulin resistance. Int. J. Clin. Pract. 51, 476–477 (1997)
pubmed: 9536592
J.R. Katz, R. Edwards, M. Khan, G.S. Conway, Acromegaly presenting with diabetic ketoacidosis. Postgrad. Med. J. 72, 682–683 (1996)
doi: 10.1136/pgmj.72.853.682
J. Vidal Cortada, J.I. Conget Donlo, M.P. Navarro Téllez, I. Halperin Rabinovic, E. Vilardell Latorre, Diabetic ketoacidosis as the first manifestation of acromegaly. An. Med. Interna 12, 76–78 (1995)
pubmed: 7749014